Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 0.63 |
| ▸ | GSK3B | P49841 | 7/20 | 0.63 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.52 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.52 |
| ▸ | PDE4A | P27815 | 1/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.51 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.51 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.50 |
| ▸ | GSK3A | P49840 | 3/20 | 0.49 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4477347 | 0.77 | MAPK14 (1.00) | MAPK14GSK3BGSK3A | |
| SCHEMBL29357806 | 0.77 | MAPK14 (0.69) | MAPK14MAPK13MAPK12KCNH2MAPK11 | |
| SCHEMBL2841705 | 0.77 | MAPK14 (0.69) | MAPK14MAPK13MAPK12KCNH2MAPK11 | |
| SCHEMBL2844566 | 0.75 | MAPK14 (0.63) | MAPK14MAPK13MAPK12KCNH2MAPK11 | |
| SCHEMBL1995900 | 0.72 | TGFBR1 (0.60) | MAPK14GSK3BMAPK13MAPK12MAPK11 | |
| SCHEMBL1992442 | 0.72 | TGFBR1 (0.57) | MAPK14GSK3BMAPK13MAPK12KCNH2 | |
| SCHEMBL2845948 | 0.72 | MAPK14 (0.74) | MAPK14MAPK13MAPK12MAPK11MAPK10 | |
| Hydrochloric Acid SCHEMBL6640025 | 0.72 | TGFBR1 (0.59) | MAPK14GSK3BMAPK13MAPK12MAPK11 | |
| SCHEMBL16105326 | 0.71 | CSNK1D (0.61) | MAPK14MAPK13MAPK12KCNH2MAPK11 | |
| SCHEMBL2840922 | 0.71 | MAPK14 (0.75) | MAPK14MAPK13MAPK12MAPK11MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210031012-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A PDE4 INHIBITOR | GLAS USA LLC | 2021-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210031012-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A PDE4 INHIBITOR | PDE4A, PDE12, PDE4B | MAPK14 2684/4885GSK3B 1280/4885MAPK13 1368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.